Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2024 Jan;38(1):74-81.
doi: 10.1002/ptr.8028. Epub 2023 Oct 6.

Pharmacovigilance of unlicensed cannabidiol in European countries

Fabrizio Calapai  1   2 , Emanuela Esposito  1 , Ilaria Ammendolia  1   2 , Carmen Mannucci  3 , Gioacchino Calapai  1 , Mariaconcetta Currò  2 , Luigi Cardia  4 , Ioanna Chinou  5
Affiliations

Pharmacovigilance of unlicensed cannabidiol in European countries

Fabrizio Calapai et al. Phytother Res. 2024 Jan.

Abstract

Cannabidiol (CBD) is a multitarget agent possessing anti-inflammatory and antioxidant properties. Unlicensed CBD gained public favor for the care of general health and well-being as well as to get comfort from inflammatory complaints, pain, anxiety, mood, and sleep disorders. Safety profile of unlicensed CBD has been not sufficiently described. For this reason, suspected adverse reactions (SARs) to CBD unlicensed products were analyzed. Serious SARs to unlicensed CBD products in EudraVigilance, a system purchased by the European Medicines Agency, were analyzed for age, sex of the patient, adverse reactions, indication for use, and concomitant drugs. Serious SARs were 18.9% of all adverse events to unlicensed CBD; they were more frequent in men and adult people and, to a less extent, in children (3-11 years). About sex, in EudraVigilance serious Individual Cases Safety Reports of SARs to CBD in men are in the largest number (58.8%) with respect to women. Unlicensed CBD was used in the 38.8% of cases for treatment of epilepsy; more frequent adverse effects were: mental disorders, hepatic disorders, and aggravation of pre-existing epilepsy. Drugs or substances more frequently associated with SARs were the antiepileptics clobazam and valproic acid, followed by cannabis. Results suggest that precautions and appropriate surveillance of adverse effects should be taken when unlicensed CBD is used.

Keywords: EudraVigilance; adverse events; adverse reactions; cannabidiol; cannabis; pharmacovigilance.

PubMed Disclaimer

References

REFERENCES

    1. Ammendolia, I., Mannucci, C., Cardia, L., Calapai, G., Gangemi, S., Esposito, E., & Calapai, F. (2023). Pharmacovigilance on cannabidiol as an antiepileptic agent. Frontiers in Pharmacology, 14, 1091978. https://doi.org/10.3389/fphar.2023.1091978
    1. Anderson, L. L., Absalom, N. L., Abelev, S. V., Low, I. K., Doohan, P. T., Martin, L. J., Chebib, M., McGregor, I. S., & Arnold, J. C. (2019). Coadministered cannabidiol and clobazam: Preclinical evidence for both pharmacodynamic and pharmacokinetic interactions. Epilepsia, 60(11), 2224-2234. https://doi.org/10.1111/epi.16355
    1. Arzimanoglou, A., Brandl, U., Cross, J. H., Gil-Nagel, A., Lagae, L., Landmark, C. J., Specchio, N., Nabbout, R., Thiele, E. A., & Gubbay, O. (2020). The cannabinoids international experts panel; collaborators. Epilepsy and cannabidiol: A guide to treatment. Epileptic Disorders, 22(1), 1-14. https://doi.org/10.1684/epd.2020.1141
    1. Bennici, A., Mannucci, C., Calapai, F., Cardia, L., Ammendolia, I., Gangemi, S., Calapai, G., & Griscti Soler, D. (2021). Safety of medical cannabis in neuropathic chronic pain management. Molecules, 26(20), 6257. https://doi.org/10.3390/molecules26206257
    1. Britch, S. C., Babalonis, S., & Walsh, S. L. (2021). Cannabidiol: Pharmacology and therapeutic targets. Psychopharmacology, 238(1), 9-28. https://doi.org/10.1007/s00213-020-05712-8